Vimarsana
Biggest News Aggregation in the World

Page 2 - Mouse Models News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mouse Models. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mouse Models Today - Breaking & Trending Today

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure - Vimarsana News

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

Published: November 10, 2023

SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination...

Source: marketscreener.com
Related Topics:
United KingdomSchleswig HolsteinMartin ReckAlan SandlerCommittee For Medicinal Products Human UseHealthcare Products Regulatory AgencyExchange CommissionEuropean Medicine AgencyMirati Therapeutics IncPrnewswire Mirati Therapeutics IncEuropean CommissionEuropean UnionMirati Therapeutic IncBristol Myers Squibb CompanyMedicinal ProductsHuman UseMirati TherapeuticsLung Clinic GrosshansdorfMirati TherapeuticBristol Myers SquibbTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical Models
Vor Biopharma : SITC – 2023 – POSTER PRESENTATION P260 -November 06, 2023 at 11:31 am EST - Vimarsana News

Vor Biopharma : SITC – 2023 – POSTER PRESENTATION P260 -November 06, 2023 at 11:31 am EST

Published: November 6, 2023

November 4, 2023 SITC - 2023 - POSTER PRESENTATION P260 Download Discovery Platform ...

Source: marketscreener.com
Related Topics:
Mouse ModelsAcute Myeloid
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - Vimarsana News

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Published: November 4, 2023

SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare...

Source: marketscreener.com
Related Topics:
United KingdomGreat BritainAlan SandlerHealthcare Products Regulatory AgencyExchange CommissionPrnewswire Mirati Therapeutics IncMirati Therapeutics IncBristol Myers Squibb CompanyMirati Therapeutic IncUniversity Hospital BirminghamMirati TherapeuticsConsultant Medical OncologistSafety InformationProduct CharacteristicsMirati TherapeuticBristol Myers SquibbTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical ModelsClinical DataMutant Non Small Cell LungClin CancerPublished April
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation - Vimarsana News

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Published: November 3, 2023

/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and...

Source: prnewswire.com
Related Topics:
United KingdomGreat BritainAlan SandlerUniversity Hospital BirminghamHealthcare Products Regulatory AgencyPrnewswire Mirati Therapeutics IncMirati Therapeutics IncExchange CommissionMirati Therapeutic IncBristol Myers Squibb CompanyMirati TherapeuticsConsultant Medical OncologistSafety InformationProduct CharacteristicsMirati TherapeuticBristol Myers SquibbTherapeutic SusceptibilityMutant CancersMouse ModelsBrain MetastasesPreclinical ModelsClinical DataMutant Non Small Cell LungClin CancerPublished April
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood ... - Vimarsana News

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood ...

Published: November 2, 2023

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support

Source: eagletribune.com
Related Topics:
Krung Thep MahanakhonRio De JaneiroEstado Do RioSan DiegoUnited StatesNoord BrabantNew YorkUnited KingdomGranda Ospedale Maggiore PoliclinicoAngelo DalessandroVan CreveldkliniekBruno FattizzoTarun AuroraThidarat SuksangplengPaola BianchiCharles JonassaintBiree AndemariamDan BudwickChris TaylorTimothy QuangAriellel LangerModupe IdowuSujit ShethJennifera RothmanAndreas Glenth